

**RECORDATI: CONCLUSION OF THE SHARE BUY-BACK PROGRAM INITIATED ON 2<sup>nd</sup> OCTOBER 2023.**

Milan, 11<sup>th</sup> April 2024 – Recordati S.p.A. announces that the share buy-back program communicated to the market on 29<sup>th</sup> September 2023 and initiated on 2<sup>nd</sup> October 2023, as per authorization granted by the Shareholders' Meeting held on 21<sup>st</sup> April 2023, with the object of the servicing of current and future stock option / performance shares plans in favour of the Recordati Group's management or share-based incentive plans that might be approved by the Company in the future, was completed on 10<sup>th</sup> April 2024.

Following-up on previous periodic updates on the execution of the program, the Company, for the period from 8<sup>th</sup> April 2024 to 10<sup>th</sup> April 2024 – on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company – informs that no purchase transactions of Recordati ordinary shares (ISIN IT0003828271) were carried out.

Therefore, Recordati S.p.A. announces to have purchased in the period from 2<sup>nd</sup> October 2023 to 10<sup>th</sup> April 2024, a total of no. 630,094 treasury shares equal to 0.301% of its share capital for a total consideration of 29,915,832.94 Euro, at an average price of 47.4784 Euro.

On 10<sup>th</sup> April 2024, the Company held no. 2,758,646 treasury shares which amount to 1.319% of the current share capital.

**Recordati** (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of € 2,082.3 million. For more information, please visit [www.recordati.com](http://www.recordati.com)

Investor Relations

Eugenia Litz  
+44 7824 394 750  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

Investor Relations

Lucia Abbatantuoni  
+39 337 1025645  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

Media Relations Brunswick:

Barbara Scalchi / Andrea Mormandi  
+39 02 9288 6200  
[recordati@brunswickgroup.com](mailto:recordati@brunswickgroup.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered office  
VIA M. CIVITALI, 1  
20148 MILAN, ITALY  
TEL. +39 0248787.1  
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up  
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI  
00748210150  
TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.à.r.l